Welcome to our dedicated page for GENESCO SEC filings (Ticker: GCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENESCO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENESCO's regulatory disclosures and financial reporting.
Meixelsperger Mary E reported acquisition or exercise transactions in this Form 4 filing.
Genesco Inc. reported that director Mary E Meixelsperger received a grant of 3,905 shares of common stock as restricted stock on 2026-07-24 under the Fourth Amended and Restated 2020 Equity Incentive Plan. Following this award, she directly owns 27,535 shares of Genesco common stock.
MARTINEZ ANGEL R reported acquisition or exercise transactions in this Form 4 filing.
Genesco Inc. reported that director Angel R. Martinez received a grant of 3,905 shares of common stock as restricted stock on 2026-07-24 under the Fourth Amended and Restated 2020 Equity Incentive Plan. Following this award, his direct holdings stood at 24,250 shares of common stock.
Lambros John F reported acquisition or exercise transactions in this Form 4 filing.
Genesco Inc. director John F. Lambros received a grant of 3,905 shares of restricted common stock on July 24, 2026, at no cash cost, as equity compensation under the company’s Fourth Amended and Restated 2020 Equity Incentive Plan.
After this award, Lambros directly owns 23,705 Genesco common shares. The transaction is reported as not made pursuant to a Rule 10b5-1 trading plan.
MARSHALL THURGOOD JR reported acquisition or exercise transactions in this Form 4 filing.
Genesco Inc director Marshall Thurgood Jr reported an award of 3,905 shares of common stock on July 24, 2026. The shares were granted as restricted stock under the Fourth Amended and Restated 2020 Equity Incentive Plan at $0.00 per share, increasing his direct holdings to 36,644 shares.
Genesco Inc. reported final voting results from its July 21, 2026 annual meeting, where a quorum was reached with 9,535,836 votes representing 85.63% of shares entitled to vote. Shareholders elected nine company nominees to the board over two nominees proposed by Bradley Radoff, with each director to serve until the 2027 annual meeting.
Shareholders approved, on an advisory basis, executive compensation with 8,188,814 votes for, and approved the Fourth Amended and Restated 2020 Equity Incentive Plan with 5,142,232 votes for and 4,300,596 against. They also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending January 30, 2027.
Genesco Inc. director Gregory A. Sandfort, through Sandfort Investments III, LLC, completed an open-market purchase of 2,958 shares of Genesco common stock at $33.80 per share on July 9, 2026. Following this indirect purchase, the LLC’s reported holdings total 29,172 shares of common stock.
Genesco Inc. is the subject of a dissident proxy solicitation by the Radoff-Jumana Group, which says it owns approximately 9.1% of outstanding shares and is nominating two directors for the 2026 annual meeting. The group released a rebuttal presentation (filed July 6, 2026) criticizing management's performance, disputing the board's use of cherry‑picked share‑price dates, and urging a Dutch tender offer for 1,000,000 shares. The presentation cites a $58.7 million tax refund and an anticipated $23–25 million tariff refund as sources of excess cash and highlights a 10‑year buyback total of ~$594.7 million for nearly 12.98 million shares at an average buyback price of $45.83. The dissidents question board refreshment, director experience, past buyback economics, and report ROIC in the very low single digits.
GENESCO INC vice president and chief accounting officer Marie Randolph reported a small share disposition related to taxes. On the vesting of restricted stock granted under the company’s Third Amended and Restated 2020 Equity Incentive Plan, 57 shares of common stock were withheld to satisfy minimum tax withholding liability. After this tax-withholding event, Randolph directly owns 7,822 shares of Genesco common stock.
Genesco shareholder activists Bradley L. Radoff, Jumana Capital Investments LLC and Christopher R. Martin (the Radoff-Jumana Group) filed a definitive proxy statement and GOLD universal proxy card seeking to elect Westervelt T. Ballard, Jr. and Paula J. Poskon to Genesco’s nine-member board at the July 21, 2026 annual meeting.
The group, which reports beneficial ownership of approximately 8.7% of outstanding common stock, urges shareholders to remove long-tenured directors Thurgood Marshall, Jr. (14-year tenure) and Joanna Barsh (13-year tenure), citing sustained negative total shareholder returns and contested past engagements. The presentation also highlights buyback analysis, executive compensation figures, and proposals to unlock value.